EUCTR2023-000804-21-Outside-EU/EEA进行中（未招募）1 期
Multicenter, Open-label, Single-arm Study to Evaluate the PK, Safety, Tolerability and Efficacy of a New Artemether:Lumefantrine (2.5 mg:30 mg) Dispersible Tablet in the Treatment of Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1) Male or female neonates/infants
- •2) Body weight <5 kg but = 2 kg
- •3) In Cohort 1, infants aged >28 days; in Cohort 2, neonates aged 1 to =28 days (3 subgroups: 1-7 days; 8-14 days; 15-28 days)
- •4) Microscopically confirmed diagnosis of P. falciparum malaria (or mixed infections):
- •in Cohort 1 of =500 and <100,000 parasites/µL asexual P. falciparum parasitemia
- •in Cohort 2 of =100 and <100,000 parasites/µL asexual P. falciparum parasitemia
- •in Cohort 2, either congenital or neonatal
- •either symptomatic or asymptomatic
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 22
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1) Head circumference < - 2 SD z-score in cm following WHO age and sex-specific reference curves (suspicion of microcephaly)
- •2) Presence of severe malaria (according to WHO 2015 definition)
- •3) HIV status :
- •-in Cohort 1, patient's or patient's mother's current treatment with ARV
- •-in Cohort 2, mother's known HIV positive status at patient's birth or mother's current treatment with ARV
- •4) Presence of the following signs of a critical condition: apnea-bradycardia, sustained bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely deteriorated general condition (based on IMCI criteria in sick infants) (WHO 2005)
- •5) Presence of any clinically significant neurological condition:
- •-any episode of convulsion during the present illness (in keeping with the IMCI list of general danger signs)
- •-known neurological disorders (e.g. chronic seizure disorders, cerebral palsy)
- •6) Presence of clinically significant abnormality of the hepatic and renal systems
- •7) Patients unable to swallow or whose drinking is impaired
- •8) Known hypersensitivity of the patient or either patient's parent to artemether, lumefantrine, any of the excipients of Coartem®/Riamet® Dispersible tablet, or to drugs of similar chemical classes
- •9) History of malabsorption or previous gastrointestinal surgery, or history of radiation therapy that could affect drug absorption or metabolism, or any other disorder or history of a condition that could interfere with drug absorption, distribution, metabolism, or excretion
- •10) Known family history of congenital prolongation of the QTc interval or sudden death or with any other clinical condition known to be associated with prolongation of the QTc interval such as history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease
- •11) Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)
- •12) Presence of any age-adjusted clinically or hematologically relevant laboratory and blood chemistry abnormalities
- •13) Patients who received any antimalarial drug, including antibiotics with antimalarial activity, within 14 days of trial start, or any other prohibited drug (see Table 6-2)
- •14) Patients who received an investigational drug within 5 half-lives of enrollment or participated in an investigational study or within 30 days, whichever is longer
研究者
相似试验
进行中（未招募）
1 期
Study to assess the safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia or Homozygous Familial HypercholesterolemiaMedDRA version: 20.0Level: LLTClassification code 10057100Term: Homozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850HypercholesterolemiaEUCTR2015-002276-25-PTAmgen Inc163
进行中（未招募）
1 期
Study to assess the safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia or Homozygous Familial HypercholesterolemiaMedDRA version: 20.0Level: LLTClassification code 10057100Term: Homozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850HypercholesterolemiaEUCTR2015-002276-25-GRAmgen Inc163
进行中（未招募）
1 期
Study to assess the safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia or Homozygous Familial HypercholesterolemiaMedDRA version: 20.0Level: LLTClassification code 10057100Term: Homozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850HypercholesterolemiaEUCTR2015-002276-25-CZAmgen Inc115
已完成
不适用
Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)Hypercholesterolemia - HeFH10027424HoFHNL-OMON55627Amgen25
进行中（未招募）
1 期
Study to assess the safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia or Homozygous Familial HypercholesterolemiaHypercholesterolemiaEUCTR2015-002276-25-PLAmgen Inc115